AdultPediatricGeriatricDosage Forms & Strengths tablet 1mg 2mg 5mg 10mg Schizophrenia Outpatient 1-2 mg PO q12hr Inpatient Initial: 2-5 mg PO q12hr Maintenance Dose: 15-20 mg/day Not to exceed 40mg/day Non Psychotic Anxiety 1-2 mg PO q12hr Maximum Dose: 6 mg/day; not to exceed 12 weeks Renal Impairment Dose adjustment not necessary following dialysisDosage Forms & Strengths tablet 2mg 5mg 10mg Schizophrenia/Psychosis Inpatient <6 years: Safety and efficacy not established 6-12 years old: 1 mg PO qDay or q12hr; not to exceed 15 mg/day 12 years old: 2-5 mg PO q12hr Initiate dosing at the low end of the range; titrate gradually Schizophrenia Outpatient - 1-2 mg PO q12hr Inpatient - Initial: 2-5 mg PO q12hr - Maintenance Dose: 15-20 mg/day - Not to exceed 40mg/day Non Psychotic Anxiety 1-2 mg PO q12hr Maximum Dose: 6 mg/day; not to exceed 12 weeksInteraction CheckerEnter a drug name and trifluoperazineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (11)amisulprideamisulpride, trifluoperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.disopyramidetrifluoperazine and disopyramide both increase QTc interval. Contraindicated.fezolinetanttrifluoperazine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsibutilidetrifluoperazine and ibutilide both increase QTc interval. Contraindicated.indapamidetrifluoperazine and indapamide both increase QTc interval. Contraindicated.metrizamidetrifluoperazine, metrizamide. Mechanism: unknown. Contraindicated. Risk of seizure. D/C phenothiazine 24h before admin. of metrizamide.pentamidinetrifluoperazine and pentamidine both increase QTc interval. Contraindicated.pimozidetrifluoperazine and pimozide both increase QTc interval. Contraindicated.procainamidetrifluoperazine and procainamide both increase QTc interval. Contraindicated.quinidinetrifluoperazine and quinidine both increase QTc interval. Contraindicated.sotaloltrifluoperazine and sotalol both increase QTc interval. Contraindicated.Serious - Use Alternative (80)abametapirabametapir will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir.aminolevulinic acid oralaminolevulinic acid oral, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.aminolevulinic acid topicaltrifluoperazine increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.amiodaronetrifluoperazine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amitriptylinetrifluoperazine and amitriptyline both increase QTc interval. Avoid or Use Alternate Drug.amoxapinetrifluoperazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.apomorphinetrifluoperazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.arsenic trioxidetrifluoperazine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrinetrifluoperazine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).bromocriptinetrifluoperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and trifluoperazine both decrease QTc interval. Avoid or Use Alternate Drug.cabergolinetrifluoperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.calcium/magnesium/potassium/sodium oxybatestrifluoperazine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.chlorpromazinechlorpromazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.clarithromycintrifluoperazine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.clomipraminetrifluoperazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.degarelixdegarelix and trifluoperazine both decrease QTc interval. Avoid or Use Alternate Drug.desipraminetrifluoperazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.dofetilidetrifluoperazine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dopaminetrifluoperazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.dosulepintrifluoperazine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.doxepintrifluoperazine and doxepin both increase QTc interval. Avoid or Use Alternate Drug.dronedaronetrifluoperazine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.droperidoltrifluoperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.epinephrineepinephrine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.epinephrine racemicepinephrine racemic and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.erythromycin basetrifluoperazine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinatetrifluoperazine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionatetrifluoperazine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearatetrifluoperazine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.fentanylfentanyl, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl intranasalfentanyl intranasal, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transdermalfentanyl transdermal, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transmucosalfentanyl transmucosal, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fluconazoletrifluoperazine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.fluphenazinefluphenazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.formoteroltrifluoperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.givosirangivosiran will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling.haloperidoltrifluoperazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.hydrocodonehydrocodone, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).imipraminetrifluoperazine and imipramine both increase QTc interval. Avoid or Use Alternate Drug.itraconazoletrifluoperazine and itraconazole both increase QTc interval. Avoid or Use Alternate Drug.ketoconazoletrifluoperazine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.levodopatrifluoperazine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.levodopa inhaledtrifluoperazine decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Phenothiazine/1st generation antipsychotics inhibit dopamine D2 receptors in varying degrees.levoketoconazoletrifluoperazine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.lisuridetrifluoperazine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.lofepraminetrifluoperazine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.lumefantrinetrifluoperazine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.maprotilinetrifluoperazine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.methyl aminolevulinatetrifluoperazine, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.methyldopatrifluoperazine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.metoclopramide intranasaltrifluoperazine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.trifluoperazine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.moxifloxacintrifluoperazine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.nilotinibtrifluoperazine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.nortriptylinetrifluoperazine and nortriptyline both increase QTc interval. Avoid or Use Alternate Drug.octreotidetrifluoperazine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.octreotide (Antidote)trifluoperazine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.olopatadine intranasaltrifluoperazine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. perphenazineperphenazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.pramipexoletrifluoperazine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.prochlorperazineprochlorperazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.promazinepromazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.promethazinepromethazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.protriptylinetrifluoperazine and protriptyline both increase QTc interval. Avoid or Use Alternate Drug.quinidinequinidine, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive cardiac effects.ropiniroletrifluoperazine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamidetrifluoperazine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.selinexorselinexor, trifluoperazine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sodium oxybatetrifluoperazine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sufentanil SLsufentanil SL, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tetrabenazinetetrabenazine and trifluoperazine both decrease QTc interval. Avoid or Use Alternate Drug.thioridazinethioridazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.trazodonetrifluoperazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.tretinointrifluoperazine, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.tretinoin topicaltrifluoperazine, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.trimipraminetrifluoperazine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.yohimbeyohimbe decreases effects of trifluoperazine by pharmacodynamic antagonism. Contraindicated.ziprasidonetrifluoperazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (335)abobotulinumtoxinAabobotulinumtoxinA increases effects of trifluoperazine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumaclidinium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineacrivastine and trifluoperazine both increase sedation. Use Caution/Monitor.albiglutidetrifluoperazine, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.albuteroltrifluoperazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilalfentanil and trifluoperazine both increase sedation. Use Caution/Monitor.almotriptanalmotriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental